Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Sibanye Stillwater Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.89 (market cap $8.04B), while Sibanye Stillwater Ltd trades at $8.52 (market cap $6.03B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Sibanye Stillwater Ltd pays a 3.63% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SBSW | |
|---|---|---|
Market Cap | $8.04B | $6.03B |
Sector | Health | Basic Materials |
52-Week High | $339.75 | $21.12 |
52-Week Low | $241.71 | $7.27 |
Enterprise Value | $7.85B | $7.66B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Sibanye Stillwater (SBSW) trades at $8.42, down 1.52% with bearish technical signals. The company shows mixed fundamentals with a negative net income margin of -3.99% and ROE of -12.38% for 2024, though revenue has stabilized at $112.13B. Recent news highlights a turnaround narrative with EBITDA growth and debt reduction plans. Technical indicators show bearish momentum with support at $8 and resistance at $9.
The stock presents a high-risk opportunity with significant upside to the $14.25 consensus price target. Key risks include persistent negative profitability, high debt levels, and commodity price volatility. Analyst sentiment is cautiously optimistic with 43% buy ratings, but investors should weigh the turnaround potential against ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
